GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » YoY EBITDA Growth

CHRO (Channel Therapeutics) YoY EBITDA Growth : 55.72% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Channel Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 55.72%.

Channel Therapeutics's EBITDA per Share for the three months ended in Dec. 2024 was $-0.30.

Channel Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Channel Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Channel Therapeutics YoY EBITDA Growth Chart

Channel Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
- -45.07 -142.72 -376.00 -8.07

Channel Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -413.74 -316.16 -125.93 -27.68 55.72

Channel Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Channel Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-1.286--1.19)/ | -1.19 |
=-8.07 %

Channel Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-0.298--0.673)/ | -0.673 |
=55.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Channel Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Channel Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Channel Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » YoY EBITDA Growth
Comparable Companies
MTVA CYCN PMCB SLXN TSBX INTS CTXR APRE TRAW HCWB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728
Website
https://www.channeltherapeutics.com
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.